Regulation of tumor recurrence by stress activated neutrophils
Regulation of tumor recurrence by stress activated neutrophils
批准号:
10416030
负责人:
Rugang Zhang
金额:
$32.53万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-01 至 2023-01-31
关键词:
AddressAdjuvantAdrenergic AgentsAdrenergic ReceptorBindingCell CycleCellsCessation of lifeCharacteristicsChemotherapy and/or radiationClinicalDNA DamageDataDevelopmentDistantDistant MetastasisElementsExcisionFelis catusFibroblast Growth FactorFibroblast Growth Factor ReceptorsGoalsHormonesHumanIn complete remissionLesionLeukotriene B4Lipid PeroxidationLipidsLipopolysaccharidesLipoxygenaseLungLymphocyteMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of ovaryMediatingModelingMusMyeloid CellsNeoplasm MetastasisNeurosecretory SystemsNon-Small-Cell Lung CarcinomaNorepinephrineOperative Surgical ProceduresParacrine CommunicationPatientsPeroxidasesPrimary NeoplasmProcessProteinsRadiation therapyReceptor SignalingRecurrenceRegulationS100A8 geneSignal TransductionSiteStressSystemTLR4 geneTP53 geneTestingTherapeutic InterventionTissuesTumor Suppressor GenesUp-RegulationWNT Signaling Pathwayautocrinebasecancer cellcancer therapycancer typechemotherapyclinically significantlung cancer cellneoplastic cellneutrophilnoveloxidized lipidpreventradiation responsereceptorreceptor for advanced glycation endproductssenescencetargeted treatmenttherapeutic targettreatment choicetreatment responsetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Complete removal of tumor lesions with surgical resection is the treatment of choice for patients with early
stages of non-small cell lung cancer (NSCLC), as well as with many other types of cancer. It often results in
cancer cure. However, substantial proportion of patients develops local or distant recurrences within
several years. It is widely accepted that small numbers of tumor cells disseminate from primary tumor site
early on during tumor development and persist in dormant state until cells re-enter the cell cycle. Cancer
cell dormancy can also be the response to radiation and chemotherapy associated with DNA damage,
which explains recurrence even after a complete response to therapies. Those dormant cells usually have
characteristics of senescent cells, thus this phenomenon is often referred as “therapy-induced senescence”
(TIS). Although signaling in dormant and senescent tumor cells is relatively well understood, much less is
known about the mechanisms that evade dormancy to form local recurrence or distant metastases years
after complete elimination of primary tumor. In this application, we model tumor cell dormancy by using two
experimental systems. The first is the induction of dormancy by regulation of the expression of tumor
suppressor gene p53 in lung cancer cells. This model allows for the study of tumor dormancy, which is not
induced by treatment with chemo- or radiation therapy and may reflect changes in tumor cells after
dissemination to tissues. The second is the model of TIS in mouse lung and human ovarian cancer treated
with chemotherapy. Our preliminary studies demonstrated that neutrophils were able to induce proliferation
of dormant tumor cells. We found that this effect could be caused by neuroendocrine adrenergic hormones
as the result of prolonged stress. We suggest a novel concept of regulation of tumor recurrence. We
propose that adrenergic hormones cause a rapid release and autocrine/paracrine signaling by S100A8/A9
proteins heterodimer leading to up-regulation of myeloperoxidase (MPO) in neutrophils. MPO and ROS
contributed to formation of oxidized lipids by neutrophils, which directly activated dormant tumor cells. The
main goal of this study is to identify the mechanism of recurrence in cancer and to determine therapeutic
targeting strategy to control this process and ultimately eliminate dormant tumor cells to prevent
recurrence. To achieve this goal, we propose the following specific aims.
Specific Aim 1. To identify specific mechanisms of neutrophil-mediated reactivation of dormant tumor
cells.
Specific Aim 2. To determine signaling in dormant tumor cells responsible for their reactivation, to identify
clinical significance and therapeutic targeting of reactivation of dormant tumor cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer
-
批准号:10731600
-
项目类别:
-
资助金额:$52.15万
-
财政年份:2023
-
负责人:Rugang Zhang
-
依托单位:
Metabolic basis of ARID1A-mutated ovarian cancer
-
批准号:10816829
-
项目类别:
-
资助金额:$36.35万
-
财政年份:2022
-
负责人:Rugang Zhang
-
依托单位:
Metabolic basis of ARID1A-mutated ovarian cancer
-
批准号:10378985
-
项目类别:
-
资助金额:$18.5万
-
财政年份:2022
-
负责人:Rugang Zhang
-
依托单位:
Regulation of tumor recurrence by stress activated neutrophils
-
批准号:10875868
-
项目类别:
-
资助金额:$24.13万
-
财政年份:2020
-
负责人:Rugang Zhang
-
依托单位:
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
-
批准号:9980335
-
项目类别:
-
资助金额:$50.98万
-
财政年份:2019
-
负责人:Rugang Zhang
-
依托单位:
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
-
批准号:10816361
-
项目类别:
-
资助金额:$37.22万
-
财政年份:2019
-
负责人:Rugang Zhang
-
依托单位:
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
-
批准号:10192683
-
项目类别:
-
资助金额:$50.98万
-
财政年份:2019
-
负责人:Rugang Zhang
-
依托单位:
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
-
批准号:10443547
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2019
-
负责人:Rugang Zhang
-
依托单位:
Overcoming platinum resistance in ovarian cancer through BET inhibition.
-
批准号:10222606
-
项目类别:
-
资助金额:$25.61万
-
财政年份:2018
-
负责人:Rugang Zhang
-
依托单位:
Overcoming platinum resistance in ovarian cancer through BET inhibition.
-
批准号:10478847
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2018
-
负责人:Rugang Zhang
-
依托单位:
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer
-
批准号:10219750
-
项目类别:
-
资助金额:$43.47万
-
财政年份:2015
-
负责人:Rugang Zhang
-
依托单位:
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer
-
批准号:10454901
-
项目类别:
-
资助金额:$11.92万
-
财政年份:2015
-
负责人:Rugang Zhang
-
依托单位:
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer
-
批准号:9380322
-
项目类别:
-
资助金额:$43.46万
-
财政年份:2015
-
负责人:Rugang Zhang
-
依托单位:
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer
-
批准号:9034830
-
项目类别:
-
资助金额:$43.46万
-
财政年份:2015
-
负责人:Rugang Zhang
-
依托单位:
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer
-
批准号:9187448
-
项目类别:
-
资助金额:$43.46万
-
财政年份:2015
-
负责人:Rugang Zhang
-
依托单位:
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer
-
批准号:10819005
-
项目类别:
-
资助金额:$30.68万
-
财政年份:2015
-
负责人:Rugang Zhang
-
依托单位:
Role of EZH2 in Epithelial Ovarian Cancer
-
批准号:8677808
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2012
-
负责人:Rugang Zhang
-
依托单位:
Role of BRCA1 Pathway in Regulating Oncogene-Induced Senescence
-
批准号:9036340
-
项目类别:
-
资助金额:$39.43万
-
财政年份:2012
-
负责人:Rugang Zhang
-
依托单位:
Role of BRCA1 Pathway in Regulating Oncogene-Induced Senescence
-
批准号:8244738
-
项目类别:
-
资助金额:$36.17万
-
财政年份:2012
-
负责人:Rugang Zhang
-
依托单位:
Role of BRCA1 Pathway in Regulating Oncogene-Induced Senescence
-
批准号:8631065
-
项目类别:
-
资助金额:$37.24万
-
财政年份:2012
-
负责人:Rugang Zhang
-
依托单位:
海外基金